Coen Steven P. sold $36K of DNA
Coen Steven P. (See remarks) sold 2,403 shares of Ginkgo Bioworks Holdings, Inc. (DNA) at $15.00 on 2026-10-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and unlikely to move the stock materially, but it provides transparency for investors monitoring insider activity.
Market read
Routine insider sale with limited trading relevance; serves primarily as a compliance disclosure.
What to watch
The insider still holds a sizable position (≈0.5% of shares), indicating continued confidence.
Background
Form 4 filings disclose insider transactions; a 10b5‑1 plan allows pre‑arranged sales, often used for portfolio rebalancing.
Ticker impact
Officer Coen Steven P. sold 2,403 shares of Ginkgo Bioworks (DNA) for $36,045 via a 10b5‑1 plan, reducing his stake to 49,448 shares.
likely modest downward pressure as the market prices the insider sale
The sale is small relative to float and disclosed via a Form 4, typical of routine 10b5‑1 transactions; no material change in ownership.
Market effects
Minimal impact on synthetic biology sector; insider sales are common and not indicative of broader trends.
None
None
Counterpoint
The sale could be a routine liquidity event, not a bearish signal; investors may ignore it.
Key entities
- CompanyGinkgo Bioworks Holdings, Inc.
Synthetic biology company listed on NASDAQ under ticker DNA.
- OfficerCoen Steven P.
Company officer executing a 10b5‑1 sale of DNA shares.
